Overview

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Status:
COMPLETED

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This study aimed to evaluate the pharmacokinetics, pharmacodynamics, and safety of SHR4640 tablets in subjects with moderate renal insufficiency and healthy subjects, and to explore the relationship between renal function (e.g., eGFR) and SHR4640 pharmacokinetic and pharmacodynamic parameters.

Phase:

PHASE1

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

ruzinurad